两种抗凝药物在癌症并发静脉血栓栓塞症患者中的应用效果比较

Application of two anticoagulant drugs in patients with cancer complicated with venous thromboembolism

目的探究利伐沙班和低分子肝素两种抗凝药物在治疗癌症并发静脉血栓栓塞症(VTE)患者中的应用效果的不同。方法选取癌症并发VTE患者72例,按照随机数字表法将患者分为对照组和实验组,实验组患者采用利伐沙班进行抗凝治疗,对照组患者采用低分子肝素进行抗凝治疗,治疗3个月后观察两组患者的治疗疗效及不良事件的发生率。结果实验组患者的总有效率高于对照组,差异具有统计学意义(χ~2=4.87,P<0.05)。两组患者不良事件发生率比较,差异无统计学意义(χ~2=3.06,P>0.05)。结论两种抗凝剂(利伐沙班、低分子肝素)治疗癌症并发VTE患者均安全有效,但低分子肝素的总有效率稍低于利伐沙班。

Objective To investigate the curative effects of rivaroxaban and low molecular weight heparin in the treatment of patients with cancer complicated with venous thromboembolism(VTE).Methods Seventy-two patients with cancer complicated with VTE were enrolled.The patients were divided into the control group and the experimental group according to the random number table method.The patients in experimental group were treated with rivaroxaban for anticoagulant therapy,and the patients in control group were treated with low molecular weight heparin.The therapeutic efficacy and the incidence of adverse reaction between two groups after 3 months of treatment were compared.Results The total effective rate of the experimental group was significantly higher than that of the control group(χ^2=4.87,P<0.05).There was no significant difference in the incidence of adverse reaction between the two groups(χ^2=3.06,P>0.05).Co?nclusion The rivaroxaban,low molecular weight heparin are all safe and effective in treatment of the cancer patients combined with VTE,but the total effective rate of low molecular weight heparin is slightly lower than that of rivaroxaban.